ALSUntangled reviews alternative and off-label treatments for people living with amyotrophic lateral sclerosis (PALS). Here we review insulin, which has at least one plausible mechanism for slowing ALS progression. However, pre-clinical studies are limited and there have been no trials in PALS yet. Insulin use in patients without a metabolic need may cause very serious and potentially lethal side effects. While further studies to evaluate potential benefits may be warranted, at this time we cannot endorse insulin treatment to slow ALS progression.

ALS Department Hospital Carlos 3 La Paz Madrid Spain

Department of Neurology Duke University Durham NC USA

Department of Neurology Loma Linda University Health Loma Linda CA USA

Department of Neurology Medical College of Wisconsin Milwaukee WI USA

Department of Neurology St Louis MO USA

Department of Neurology Temple Health Philadelphia PA USA

Department of Neurology University of Miami Miami FL USA

Department of Neurology University of Michigan Ann Arbor MI USA

Department of Neurology University of Nebraska Medical Center Omaha NE USA

Department of Neurology University of Utah Salt Lake City UT USA

Department of Neuroscience University of North Carolina Chapel Hill NC USA

Department of Neuroscience University of Sheffield Sheffield South Yorkshire UK

Department of Rehabilitation Elson S Floyd College of Medicine Washington State University Spokane WA USA

Independent Consultant Lichfield England UK

Institute of Biology and Medical Genetics Charles University Prague Czech Republic and

Medical School Duke University Durham NC USA

Neurology Department University of Tennessee Health Science Center Memphis TN USA

UNC Health UNC Chapel Hill NC USA

Undergraduate Duke University Durham NC USA

Undergraduate Tulane University New Orleans LA USA

University of North Carolina at Chapel Hill Chapel Hill NC USA

Amyotroph Lateral Scler Frontotemporal Degener. 2024 May;25(3-4):II. doi: 10.1080/21678421.2024.2341556. PubMed

References provided by Crossref.org